NCT05688852TERMINATEDanonymous

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease

Sponsor

Source record

Ventyx Biosciences, Inc

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

VTX958, VTX958, VTX958 Placebo

Indication / condition

AI-normalized

Crohn Disease

Intervention

Source record

VTX958, VTX958, VTX958 Placebo

Source & freshness

Source record

NCT ID

NCT05688852

Original source

ClinicalTrials.gov

Source last updated

Jul 03, 2025

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05688852

Title

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease

Sponsor

Ventyx Biosciences, Inc

Status

TERMINATED

Phase

PHASE2

Condition raw

Crohn Disease

Condition normalized

Crohn Disease

Modality raw

small molecule

Modality normalized

small molecule

Target raw

VTX958, VTX958, VTX958 Placebo

Target normalized

VTX958, VTX958, VTX958 Placebo

Interventions

VTX958, VTX958, VTX958 Placebo

Public preview

Source record

This is a multicenter, randomized, double-blind placebo-controlled, parallel group study to evaluate the efficacy and safety of VTX958 in participants with moderately to severely active Crohn's Disease.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants With Moderately to Severely Active Crohn's Disease

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT05688852

Status

TERMINATED

Phase

PHASE2

Sponsor

Ventyx Biosciences, Inc

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedJul 03, 2025

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05688852

Indication

Crohn Disease

Modality

small molecule

Target

VTX958, VTX958, VTX958 Placebo

Intervention

VTX958, VTX958, VTX958 Placebo

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.